Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation
This article was downloaded by: [UNAM Ciudad Universitaria]On: 14 February 2013, At: 11:09Publisher: Taylor & FrancisInforma Ltd Registered in England and Wales Registered Number: 1072954 Registered office: MortimerHouse, 37-41 Mortimer Street, London W1T 3JH, UK
British Poultry Science Publication details, including instructions for authors and subscription information:
Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long- acting formulation L. Gutiérrez a , D. Vargas-Estrada a , C. Rosario b & H. Sumano a a Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Av. Universidad 3000, Delegación Coyoacán, Ciudad de México C.P. 04510 b Departamento de Producción Animal, Aves, Universidad Nacional Autónoma de México, Av. Universidad 3000, Delegación Coyoacán, Ciudad de México C.P. 04510, México To cite this article: L. Gutiérrez , D. Vargas-Estrada , C. Rosario & H. Sumano (2012): Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation, British Poultry Science, 53:3, 366-373 To link to this article:
This article may be used for research, teaching, and private study purposes. Any substantial or systematicreproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form toanyone is expressly forbidden.
The publisher does not give any warranty express or implied or make any representation that the contentswill be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug dosesshould be independently verified with primary sources. The publisher shall not be liable for any loss, actions,claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly orindirectly in connection with or arising out of the use of this material.
British Poultry Science Volume 53, Number 3 (June 2012), pp. 366—373
Serum and tissue concentrations of doxycycline in broilers after thesub-cutaneous injection of a long-acting formulation
´RREZ, D. VARGAS-ESTRADA, C. ROSARIO1 AND H. SUMANO
Departamento de Fisiologı´a y Farmacologı´a, Facultad de Medicina Veterinaria y Zootecnia, UniversidadNacional Auto´noma de Me´xico, Av. Universidad 3000, Delegacio´n Coyoaca
and 1Departamento de Produccio´n Animal, Aves, Universidad Nacional Auto´noma de Me´xico, Av. Universidad3000, Delegacio´n Coyoaca
´n, Ciudad de Me´xico C.P. 04510, Me´xico
1. The antibacterial agent doxycycline hyclate (Dox) is usually administered to broilers in
drinking water or as a feed supplement. Parenteral injection is not the usual route for administration, soa long-acting formulation (Dox-LA) was tested to evaluate if serum concentrations can achieve thepharmacokinetic/pharmacodynamic (PK/PD) ratios regarded as adequate for the drug. 2. A poloxamer-based matrix was used to provide Dox-LA. Serum and tissue concentrations of Dox vstime were determined in two day-old broilers after subcutaneous (SC) injection of Dox-LA or oraladministration of a single bolus of aqueous Dox (Dox-PO), at a dose of 20 mg/kg. Weight gain, feedconversion rate, haematological variables, aspartate aminotransferase and alanine aminotransferaseactivities, blood urea and creatinine were determined and compared for Dox-LA with Dox-PO and non-medicated controls. 3. Dox-LA had a high relative bioavailability (1200%). Maximum serum concentrations were notstatistically different (5Á1 Æ 1Á1 mg/ml for Dox-LA and 6Á1 Æ 1.4 mg/ml for Dox-PO), but half-life of Dox-LAwas much greater than the value obtained for Dox-PO (73Á0 Æ 0Á9 h and 2Á0 Æ 0Á02 h, respectively). Tissueconcentrations were higher, and stayed higher for longer periods in the Dox-LA group. 4. In conclusion, considering the minimum effective serum concentration against Mycoplasma spp is0Á5 mg/ml, a dose-interval of 180 h can be achieved with Dox-LA, but only for 24 h after Dox-PO. BetterPK/PD ratios for Dox-LA should result in improved clinical outcomes compared with Dox-PO.
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
therapeutic agent. Doxycycline is a tetracyclinederivative with broad spectrum activity against
Parenteral administration of drugs to newly-
Gram-positive and Gram-negative aerobic and
hatched broilers is not a common practice, this
Chlamydia and Rickettsia species (Shaw and
(Vermeulen et al., 2002). When necessary, meta-
Rubin, 1986; Dorrestein et al., 1990; Goren
phylactic and therapeutic doses of antibacterial
drugs are administered to broilers with the
Doxycycline has some advantages over older
drinking water or as in-feed medication during
tetracycline derivatives including higher lipid
the first days after hatching; for example, to
solubility, better bioavailability and tissue distri-
control Mycoplasma spp and associated infections
bution, longer elimination half-life, and lower
(Ismail and El-Kattan, 2004; Stipkovits et al.,
affinity for calcium ions (Aronson, 1980).
´rez et al., 2006). Among such antibacter-
ial drugs, doxycycline (-6-deoxy-5-hydroxytetra-
oral administration have been studied in healthy
cycline) has gained a reputation as a valuable
chickens (Anadon et al., 1994; Laczay et al., 2001)
´ctor Sumano, Departamento de Fisiologı´a y Farmacologı´a, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional
´noma de Me´xico, Av. Universidad 3000, Delegacio
´n Coyoaca´n, Ciudad de Me´xico C.P. 04510, Me´xico. E-mail: sumano@servidor.unam.mx
Accepted for publication 8th November 2011.
ISSN 0007–1668(print)/ISSN 1466–1799 (online)/12/030366—8 ß 2012 British Poultry Science Ltdhttp://dx.doi.org/10.1080/00071668.2012.701004
CONCENTRATIONS OF A LONG-ACTING DOXYCYCLINE IN BROILERS
and in Mycoplasma gallisepticum-affected broilers
included in a reverse gel copolymer polyoxypro-
pyl-polyoxyethylene (poloxamer) (BASF, Mexico
Bioavailability has been determined as approxi-
City, Mexico), adjusting pH to 7Á0 with a phos-
mately 65—70% but there is no parenteral formu-
phate buffer solution with constant stirring at 4C
lation available due to causing severe tissue
to produce a final concentration of 10% Dox in
irritation. A possible exception is an experimen-
15% poloxamer. The preparation was completed
(Dox-LA) preparation that causes minimum irri-
mixture clarified. Quantities (10 ml) were dis-
tation and exhibits high bioavailability values
pensed into vials, stored at 4C and utilised
(4600%) in goats (Vargas et al., 2008), calves
(Vargas-Estrada et al., 2008a) and rats (Vargas-Estrada et al., 2008b). Considering the above, itwas considered useful to evaluate and compare
the pharmacokinetic parameters of this prepara-
A total of 5 groups were formed as follows.
tion with two-day-old broilers compared with
Group 1 containing 400 broilers was dosed with
those obtained after oral administration of an
the experimental preparation (Dox-LA) at approx-
aqueous doxycyclin solution (Dox-PO).
imately 1 mg/broiler ($ 20 mg/kg) in a totalvolume of 200 ml using a precision syringe
(syringe for oily vaccine, Broiler ND KÕ,CEVAC; Barcelona, Spain) for pharmacokinetic
determination. Group 2 (200 broilers) received asimilar Dox-LA dose and these broilers were used
The study was approved by the Institutional
to investigate any side effects such as tissue
damage. Production variables were determined
Nacional Autonoma de Mexico, according to
during the following 6-week period. In both these
the Mexican Official Regulation NOM-062-ZOO-
groups, birds were observed for up to 20 min
1999. The experiment was carried out in isola-
after injection to detect any changes in behav-
tion units at the Universidad Nacional Autonoma
iour. Groups 3 (400 broilers) and 4 (200 broilers)
´xico in Mexico City, with a total of 1,400
were given oral doxycyclin (Dox PO) to compare
two-day-old broiler chickens having a mean
the pharmacokinetics and production variables,
(Æ SD) weight of 48 Æ 2Á4 g as determined by
respectively. These two groups were treated with
weighing 10% of the population. Upon arrival,
a single oral dose of a freshly diluted 0Á5%
broilers were allowed to settle and water was
aqueous solution of doxycycline hyclate by means
made available ad libitum through nipple-type
of rigid tubing into the proventriculus in a
dispensers at 20 birds per cup (Marks, 1981;
volume of 200 ml. Group 5 was the untreated
Quintana, 1988). House temperature was main-
control group (CG with 200 broilers) and dosed
tained at 30 Æ 1Á5C using gas heaters and a
orally with 200 ml of saline solution.
Sampling times were selected to provide the
least amount of error in the estimate of thepharmacokinetic parameters. To analyse concen-
trations of doxycycline in tissues, 15 broilers
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
A subcutaneous Dox-LA preparation (100 mg/ml) of
from each group were killed, as specified by
doxycycline hyclate (PARFARM Pharmaceuticals,
Mexican regulations (NOM-009-Z00-1994), 6 h
Mexico City, Mexico) was produced under sterile
after dosing and then daily for 6 d. The small
conditions. Inclusion complexes of doxycyclin
intestine, large intestine plus caecum-rectum,
10% (w/v) with -cyclodextrin (1:0Á1 M) (Cerestar
liver, lungs and yolk sac from each animal were
Pharmaceutical Excipients, Hammond IN, USA)
dissected and stored in Eppendorf tubes at
were first formed by the kneading method which
À20C until analysed. Because of the small
can be described as follows: -cyclodextrin (0Á1 M)
amount of small intestine and yolk sac collected
and distilled water were mixed together in a
from each broiler, three separate samples, each
mortar to produce a homogeneous paste.
made up of tissue from 5 broilers, were needed
Doxycycline (1 M) was added slowly. The mixture
to obtain sufficient material for determination of
was ground for 30 min and an appropriate quan-
doxycycline concentration. Yolk sac was only
tity of water added to produce a paste-like
determined for 5 d (7 day-old broilers) until this
consistency. This was dried at 40—50C for 24 h.
tissue was no longer detectable. Tissue reactions
The dried complex was pulverised into a fine
at the site of injection were investigated in all
powder (Bekers et al., 1991). The resulting powder
broilers from the Dox-LA-treated groups during
was diluted with a solution of 15% propylenegly-
an 8 d follow-up period. For groups Dox-LA
col — 10% ethyl alcohol in water. This mixture was
(Group 1) and Dox-PO (Group 3), 5 broilers
were sampled for blood by direct jugular punc-
Percent recovery achieved was 86Á5%, with intra-
ture using a one ml syringe and 30 gauge needle
and inter-assay coefficients of variation of 5% and
at the following times: before treatment and at 1,
2, 4, 6, 8, 12, 24, 26, 28, 30, 32, 36, 48, 50, 52, 54,
56, 60, 72, 74, 76, 78, 80, 84, 96, 98, 100, 102, 104,
PKAnalyst (MicroMathÕ, Saint Louis, Missouri,
108, 120, 122, 124, 126, 128, 132, 144, 146, 148,
USA), was used to fit and analyse the concentra-
150, 152, 156, 168, 170, 172, 174, 176, 180 and
tion-versus-time patterns for each group. Models
196 h. In Group 2, Group 3 and Group 5, blood
of best fit (r ! 0Á99) were chosen after analysis by
samples were obtained from 10 broilers ran-
use of residual sum of squares and the minimal
domly chosen before the start of the experiment,
Akaike’s information criterion (Welling, 1997).
and at weekly intervals for 6 weeks for haemato-
Best fit for the SC route was obtained by use of
logical analysis (cell volume, red blood cell
counts, total white blood cell count and haemo-globin concentration). Aspartate aminotransfer-
activities were determined using an autoanalyser
(CELLY 70 Autoanalyzer, Chronolab SA de CV,Mexico City). Finally, blood urea nitrogen and
Variables obtained were: AUCt ¼ area under the
creatinine were determined as described by
curve; AUMC0—1 ¼ area under the first moment
Boisness and Taussky (1985). Production vari-
curve from 0 to 1 with extrapolation of the
ables (weekly weight gain, feed conversion rate
terminal phase; MRT ¼ mean residence time;
and cumulative mortality) were assessed in these
¼ rate constant for the elimination phase;
T½ ¼ elimination half life; T½ab ¼ absorption
Within the next three weeks from the end of
the experiment, samples were thawed and doxy-
cycline concentrations in serum and tissue sam-
For Dox-PO, the following general formula
ples determined by the quantitative/qualitative
agar plate diffusion method (Bennet et al., 1966)
Laboratories, Detroit, MI, USA) and Bacillus
¼ AeÀÁTime þ BeÀÁTime þ CeÀKabÁTime
cereus var. mycoides (ATTCC, 11778) as testorganism. This method measured concentration
Variables obtained were as above. Relative
bioavailability was calculated as follows:
chosen bacterium was seeded at an approximate
inoculum of 5 Â 105 CFU/ml in Mueller-Hinton
City, Mexico) and using chicken serum as dilu-
Data are presented as mean Æ standard devi-
ent. No baseline activity with blank serum was
ation for three sets of observations for each
detected. Percentage recovery achieved with this
parameter; and for statistical comparisons of
technique was 92Á5 Æ 3Á5%. The limit of quanti-
Cmax, Tmax, AUCt, MRT and T½ among groups
fication (LOQ) was 0Á01 mg/ml identified by
the ANOVA was followed by a Bonferroni-test.
means of doxycycline enriched serum samples,
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
which correspond to 8Á0 mm of inhibition halo asmeasured
Correlation coefficient of the standard solutionof doxycycline was 0Á95. Intra-assay and inter-
Broilers did not manifest signs of pain or
assay coefficients of variation were 55% and
discomfort after injection of the Dox-LA formu-
lation, and no inflammatory response was evi-
dent at the injection site. A small painless
(T25 Top Ultra Turrax, Staufen, Germany) in
swelling was detectable in some broilers. These
2Á0 ml potassium phosphate buffer (0Á1 M, pH 4Á5)
swellings had an initial size of approximately
and centrifuged at 3000 g for 15 min. The super-
2—4 mm in diameter and gradually disappeared
natant layer was transferred to a clean tube.
Triplicates of each tissue sample as well asstandard concentrations in different matrices
Haematological, as well as blood urea and creat-
(100 ml) were pipetted into individual wells
inine and liver enzyme activities remained within
made in agar plates and were incubated for
the accepted limits for the species and a distin-
18 h at 37C. The limit of quantification was
guishable pattern or change between groups was
0Á01 mg/ml, with 8 mm diameter as the lowest
not detected (data not shown). Table 1 shows
calibration standard on linear standard curves.
CONCENTRATIONS OF A LONG-ACTING DOXYCYCLINE IN BROILERS
cumulative mortality in groups 2, 4 and 5. Mean
and T½, showed that all these variables were
significantly greater in the Dox-LA treated group
doxycycline for group 1 (Dox-LA) and group 3
than in the Dox-PO group (P50Á01). The differ-
(Dox-PO) are shown in Figures 1 and 2 and the
ence between mean elimination half-lives of
determined pharmacokinetic variables are sum-
73 Æ 0Á9 h for Dox-LA and 2 Æ 0Á02 h for Dox-PO
marised in Table 2. Comparisons for AUCt, MRT
was highly significant (P50Á001). In contrast,Cmax was greater in the Dox-PO group (6Á1 mg/mlin Dox-PO vs. 5Á1 mg/ml in Dox-LA) (P50Á05).
Table 1. Mean Æ SD weight gain, feed conversion rate and
A flip-flop pharmacokinetics of this prepara-
cumulative mortality in broilers after a single dose of
tion is postulated applying Boxenbaum (1998)
doxycycline (20 mg/kg) administered either by subcutaneous
and Laczay et al. (2001) criteria with the following
injection (Dox-LA, 200 broilers) or orally (Dox-PO, 200
broilers). Values of an untreated control group (200 broilers)
where Vz is the terminal exponential volume ofdistribution; K is the terminal disposition rate
constant once drug absorption is complete (best
determined from IV dosing); C is the plasma
concentration at time t; and ÁC is the change in
plasma concentration over the time interval Át.
For Dox-LA plasma concentration—time data at 24
and 48 h, ÁC/Át ¼ 0Á03 mg/ml/h. At the mid-
point of this time period (36 h), (K)(C) ¼ 4Á1 mg/
ml/h. Since KC ) ÁC/Át, and rate of absorp-
tion % rate of elimination, a ‘‘flip-flop’’ condition
exists and the Dox-LA here described can be
The agar diffusion technique used here to deter-
a—iDifferent letters within a week-row are statistically significant (P50Á05)
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
90 100 110 120 130 140 150 160 170 180 190
Mean and SD serum concentrations of doxycycline after the subcutaneous injection of a single dose of 20 mg/kg of a
doxycycline-LA experimental preparation (Dox-LA), and after administering the same dose orally with a semi-rigid tube (Dox-PO).
Mean Æ 1 SD concentrations of doxycycline in lungs, small intestine, vitellin sac, large intestine plus caecum, and liver
after the subcutaneous injection of a single dose of 20 mg/kg of a doxycycline-LA experimental preparation (Dox-LA, n ¼ 15) in a totalvolume of 200 ml on the second day after hatching; or after administering an aqueous solution of the drug by directly depositing it intothe crop with a semi-rigid tube (Dox-PO, n ¼ 15) using the same dose and volume.
doxycycline is a dependable method, allowing
Table 2. Mean Æ SD pharmacokinetic parameters in broilers
pharmacokinetic data to be extrapolated to
after a single dose of doxycycline (20 mg/kg) administered either
antibacterial activity with certainty (Santos et al.,
by subcutaneous injection (Dox-LA) or orally (Dox-PO).
1996; Vargas et al., 2008; Vargas-Estrada et al.,
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
been reported in chickens following oral, intra-
venous (IV) and intramuscular (IM) administra-
et al., 2001; Atef et al., 2002; Ismail and El-Kattan,
2004; El-Gendi et al., 2010). The elimination half-
life of doxycycline following oral administration
varies with age between 10 and 12 h (Pashov and
Kamelov, 1994; Hantash et al., 2008). However,
these values are notably different from the T½
values of 3Á64 to 4Á75 h reported by Anado
AUCt ¼ area under the curve; AUC0—1 ¼ area under the curve to infinity;
(1994), Atef et al. (2002) and El-Gendy et al.
MRT ¼ mean residence time; T½ ¼ half life of the elimination;
(2010). In the present study a T½ of 2Á0 Æ 0Á02
T½ab ¼ half life of the absorption; Kel ¼ constant for drug elimination;
Tmax ¼ peak time; VdAUC ¼ apparent volume of distribution based on
explained by the use of an oral bolus dose.
trapezoid AUC; Fr ¼ relative bioavailability, n ¼ 400
Elimination half life after IM and SC administra-
1 Calculated for flip-flop pharmacokinetics (Concordet, 2010).
tion of a large dose of 100 mg/kg were reported
CONCENTRATIONS OF A LONG-ACTING DOXYCYCLINE IN BROILERS
to be 86 and 63 h, respectively (Greth et al.,
1993). In contrast, Atef et al. (2002) report a half-
(Yoshida et al., 1990; Uekama et al., 1998).
life of only 2Á5 h after the IM administration of
Because injection of Dox-LA failed to induce
15 mg/kg. In the present study, T½ in the group
significant changes in haematological variables,
receiving Dox-LA was 73 h. These differences may
or a reduction in production values, lack of
be explained by the dose (Greth et al., 1993)
toxicity of this drug preparation is envisaged.
causing an inflammatory reaction and a depot-
It has been postulated that maximum effi-
like effect, whereas a real depot effect is likely to
cacy in a clinical setting with Dox is achieved
have been obtained in this study without an
when serum concentrations of the drug are
barely at or above the MIC level for the pathogen
in question, for as long as possible within the
LA and Dox-PO groups (5—6 mg/ml) were higher
dosing interval (Craig, 1998; Prescott et al., 2000).
than values obtained after dosing fasted or fed
Values of MIC that can be adopted in this
broilers with this drug (3Á07 mg/ml to 4Á47 mg/ml,
experiment can be categorised as susceptible
respectively; Laczay et al., 2001), but they were
similar to those reported by Atef et al. (2002)
Takahashi and Yoshida, 1989; Stipkovits et al.,
after IM administration of 15 mg/kg (6Á33 mg/
2004) and less susceptible for Escherichia coli
ml) and Hantash et al. (2008) after oral admin-
(1—4 mg/ml: Cunha et al., 1982). Additionally,
Notari (1987) suggested a MTC from 0Á5 to 1 mg/
Predictably, for a highly lipid soluble drug
ml for this antibacterial drug and a similar value
such as doxycycline, a high value of the apparent
has been advanced for broilers (Hantash et al.,
volume of distribution AUC was achieved with
2008). Considering the above, a MTC range for
Dox-LA, with a very small total body clearance.
susceptible bacteria can be set from 0Á5 mg/ml to
The apparent VdAUC value derived from Dox-PO
1Á5 mg/ml. Hence, the length of time in which
is similar to the one reported by Hantash et al.
MTC can be achieved with Dox-PO varies from
(2008) and almost double that reported by Atef
10 h to 24 h, and for Dox-LA this interval is
et al. (2002). However, no studies are available on
extended from 150 to 180 h. If lung concentra-
the pharmacokinetics following SC injection of a
tions of doxycycline are considered as key values
to design a dosing scheme, then SC administra-
Relative Dox bioavailability for the Dox-LA
tion of Dox-LA is considerably superior as com-
group was 1200% as compared with the Dox-PO
pared with administering doxycycline through
group. Absolute bioavailability in other studies
the drinking water. Concentrations in lung
was never greater than 70% when comparing the
higher than 0Á4 mg/ml are extended until d 6 in
the Dox-LA group with a single dose of 20 mg/kg,
Although these values of F cannot be directly
injected SC. This is consistent with the unusually
compared, differences appear substantial. This is
not uncommon for formulations with prolonged
dictor of therapeutic efficacy for tetracyclines in
humans, is the ratio AUC at steady state (AUCss)/
´lou, 2004). A recycling phenomenon due to
the noticeably high lipid solubility of Dox may
was not evaluated in this study, if a pathogen is
have contributed to these differences (Aronson,
susceptible at 1Á5 mg/ml, the AUCDox-LA/MIC
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
ratio achieves a value of 407. In contrast, the
The rationale behind the design of the Dox-
AUCDox-PO/MIC ratio is only 32. Differences are
LA preparation was to use the poly (ethylene
considerable and clinical efficacy should be
higher. Additionally, Dox-LA provides reasonably
oxide) block copolymer (poloxamer) as delivery
steady serum concentrations for 5 d, while oral
vehicle-matrix, because it improves solubility,
administration of the drug over such a period will
reduces hydrolytic degradation, achieves con-
vary according to water consumption with daily
trolled release and often results in improved
Doxycycline is effective against respiratory
Kabanov et al., 1992). The poloxamer exhibits
pathogens in avian medicine, as well as in other
low viscosity at room temperature (28—32C) and
domestic species, because it penetrates well into
becomes a gel at body temperature (37—40C)
respiratory tissues (Anadon et al., 1994; Atef et al.,
(Schmolka, 1991), thus allowing the long-acting
2002; Ismail and El-Kattan, 2004). By injecting
effect observed. Additionally, reduced irritation
Dox-LA, this feature seems to be boosted, and is
is postulated to be due to -cyclodextrin by
longer-lasting compared with Dox-PO. This is
reducing the local concentration of free drug
likely to be beneficial when treating susceptible
below the irritancy threshold (Szejtli, 1985;
pathogens such as Mycoplasma spp, E. coli and
Yoshida et al., 1990; Uekama et al., 1998).
others. Additionally, the gastrointestinal system
is one of the main routes for elimination of
infection. Deutsche Veterinaar Medizinische Gesellschaft,
doxycycline, which is therefore effective against
colibacillosis and other enterobacterial infec-
L-GENDI, A.Y.I., ATEF, A., AZIZA, M.M. & KAMEL, G.M. (2010)
Pharmacokinetic and tissue distribution of doxycycline in
tions, as the same reasoning applies.
broiler chickens pretreated with either: diclazuril or
In conclusion, Dox-LA is a preparation that
halofuginone. Food and Chemical Toxicology, 48: 3209–3214.
optimises PK/PD congruency in broilers and
GOREN, E., DE-JONG, W.A., DOORNENBAL, P. & LAURENSE, T.
provides at least 4 d of medication, making it
(1998) Therapeutic efficacy of doxycycline hyclate in
more cost effective and perhaps more ecologi-
experimental Escherichia coli infection in broilers. TheVeterinary Quarterly, 10: 48–52.
cally sound. Nevertheless, clinical trials and drug-
GRETH, A., GERLACH, H., GERBEMANN, H., VASSART, M. &
residue studies are needed to assess if this
RICHEZ, P. (1993) Pharmacokinetics of doxycycline after
preparation can be regarded as potentially
useful at a production level. Further assessment
(Chlamydotis undulata). Avian Diseases, 37: 31–36.
of the safety of this preparation in broilers is
ABUDABOS, A.M. (2008) Pharmacokinetics and bioequiva-
lence of doxycycline (ProvidoxÕ and Doxyvet 0—50 SÕ)oral powder formulations in chickens. International Journal
ISMAIL, M.M. & EL-KATTAN, Y.A. (2004) Disposition kinetics of
This study was supported by a grant (60303) from
doxycycline in chickens naturally infected with Mycoplasmagallisepticum. British Poultry Science, 45: 550–556.
KABANOV, A.V., BATRAKOVA, E.V., MELIK-NUBAROV, N.S.,
de Ciencia y Tecnologı´a (SEP-CONACyT), Mexico.
CHEKHONIN, V.P., NAZAROVA, I.R. & KABANOV, V.A. (1992)A new class of drug carriers: micelles of poly (oxyethy-
lene)-poly (oxypropylene) block copolymers as microcon-
tainers for drug targeting from blood in brain. Journal of
P., FERNANDEZ, M.C., FERNANDEZ-CRUZ, M.L.,
LACZAY, P., SEMJE´N, G., LEHEL, J. & NAGY, G. (2001)
TURBE, J. & MARTINEZ, M.A. (1994) Pharmacokinetics of
doxycycline in broiler chickens. Avian Pathology, 23: 79–90.
Pharmacokinetics and bioavailability of doxycycline in
fasted and nonfasted broiler chickens. Acta Veterinaria
RONSON, A.L. (1980) Pharmacotherapeutics of the newer
tetracyclines. Journal of the American Veterinary Medical
MARKS, H.L. (1981) Role of water in regulating feed intake
and feed efficiency of broilers. Poultry Science, 60: 698–707.
TEF, M., YOUSSEF, S.H.A., EL-EANNA, H.A. & EL-MAAZ, A.A.
(2002) Influence of alatoxin B1 on the kinetic and
NOM-009-Z00-1994, SARH. Norma Oficial Mexicana NOM-
disposition, systemic bioavailability and tissue residues of
009-Z00-1994, Proceso sanitario de la carne. Diario Oficial De
NOTARI, R.E. (1987) Biopharmaceutics and clinical pharma-
cokinetics an introduction, Principles of pharmacokinetics:
˜ OS, D.J.E. & FERRE´, A.M. (2002) Bases cientı´ficas de la
utilizacio´n de medicamentos. In Principios de farmacologı´a
dosage regimen, 4th ed., pp. 45—212 (New York, M Dekker).
PASHOV, D. & KANELOV, I. (1994) Influence of age on
pharmacokinetics of doxycycline and of formulation
EKERS, O., UIJTENDAAL, E.V., BEIJNEN, J.H., BULT, A. &
NDERBERG, W.J.M. (1991) Cyclodextrins in the pharma-
ceutical field. Drug Development and Industrial Pharmacy,
Proceedings of the 6th EAVPT Congress, Edinburgh, 64—65.
PE´REZ, B.T., ROSADO, R.I. & SA´NCHEZ, M.L. (2006) Vacunas
BENNET, J.B., BRODIE, J.L., BENNER, E.J. & KIRBY, W.M. (1966)
Simplified accurate method for antibiotic assay. Clinical
electro´nica de Veterinaria, VII,1—22 http://redalyc.uae-
specimens. American Society of Microbiology, 14: 170–177.
mex.mx/src/inicio/ArtPdfRed.jsp?iCve=63612653034
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
BOISNESS, R.W. & TAUSSKY, H.H.J. (1985) Determination of
creatinine in plasma and urine. Journal of Biological
PRESCOTT, J.F., BAGGOT, J.D. & WALKER, R.D. (2000)
Antimicrobial Therapy in Veterinary Medicine, 3th ed.,
BOXENBAUM, H. (1998) Pharmacokinetics tricks and traps: flip-
pp. 275—289 (Ames, USA, Iowa State University Press).
flop models. Journal of Pharmacy and Pharmaceutical
QUINTANA, J.A.L. (1988) Manejo de la parvada, The Avitecnia:
CHOPRA, I., HOWE, T.G.B., LINTON, A.H., LINTON, K.B.,
RICHMOND, M.H. & SPELLER, D.C.E. (1981) The tetracy-
RIVIERE, J.E. & SPOO, J.W. (2003) Tetracycline antibiotics, in:
clines: prospects at the beginning of the 1980s. Journal of
ADAMS, H.R. (Ed.) Farmacologı´a y Terape´utica Veterinaria,
Antimicrobial Chemotherapy, 8: 5–21.
CONCORDET, M. (2010) Volumes of distribution. Physiologie et
SANTOS, M.D.F., VERMEERSCH, H. & REMON, J.P. (1996)
Validation of a high-performance liquid chromatographic
CRAIG, W.A. (1998) Pharmacokinetic/pharmacodynamic
method for the determination of doxycycline in turkey
parameters: rationale for antibacterial dosing of mice
plasma. Journal of Chromatography, 682: 301–308.
and men. Clinical Infectious Diseases, 26: 1–12.
SCHMOLKA, I.R. (1991) Poloxamers in the pharmaceutical
industry, in: TARCHA, P.J. (Ed.) The Polymers for Controlled
Pharmacodynamics of Doxycycline. Clinical Microbiology
Drug Delivery, pp. 189—214 (Boca Raton, FL, CRC Press).
SHAW, D.H. & RUBIN, S.T. (1986) Pharmacologic activity of
DORRESTEIN, G.M., WELINK, J. & HAAGSMA, N. (1990)
doxycycline. Journal of the American Veterinary Medical
Pharmacokinetic differences for doxycycline between
racing pigeons (Columba livia) and collared doves
STIPKOVITS, L., MARCA, J., SISQUELLA, L. & NAVARRETE, E. (2004).
(Streptopelia decaveto) and the effect of a salmonella
CONCENTRATIONS OF A LONG-ACTING DOXYCYCLINE IN BROILERS
incrementar la eficacia del tratamiento con tetraciclinas en
long—action parenteral formulation of doxycycline hyclate
pollos infectados experimentalmente con Mycoplasma
gallisepticun. Available: http://www.manolofolio.co.uk/
calier/articulos/aves/avesnov04.pdf.
VARGAS-ESTRADA, D., GRACIA-MORA, J. & SUMANO, H. (2008a)
SZEJTLI, J. (1985) Molecular Entrapment and release proper-
Pharmacokinetic study of an injectable long-acting par-
ties of drugs by cyclodextrins, in: SMOLEN, V.F. (Ed.)
enteral formulation of doxycycline hyclate in calves.
Controlled Drug Bioavailability, Vol. 3. pp. 365—421 (New
Research in Veterinary Science, 84: 477–482.
VARGAS-ESTRADA, D., JUAREZ, I., GUTIE´RREZ, L. & SUMANO, H.
TAKAHASHI, I. & YOSHIDA, T. (1989) Antimycoplasmal activities
(2008b) Serum and tissue concentrations of an experi-
of ofloxacin and commonly used antimicrobial agents on
mental long—acting parenteral formulation of doxycycline-
Mycoplasma gallisepticum. Japanese Journal of Antibiotic,
hyclate in Wistar rats. Arzneimittel Forschung (Drug
TARR, B.D. & YALKOWSKY, S.H. (1987) A new parenteral
VERMEULEN, B., DE BECKER, P. & REMON, J.P. (2002) Drug
vehicle for the administration of some poorly water
administration to poultry. Advanced Drug Delivery Reviews,
soluble anti-cancer drugs. Journal of Parenteral Science and
WELLING, P.G. (1997) Processes, mathematics and applica-
TOUTAIN, P.L. & BOUSQUET-MELOU, A. (2004) Bioavailability
tions, Pharmacokinetics, 2th ed., pp. 11—34 (Washington
and its assessment. Journal of Veterinary Pharmacology and
YOSHIDA, A., YAMAMOTO, M., ITOH, T., IRIE, T., HIRAYAMA, F. &
UEKAMA, K., HIRAYAMA, F. & IRIE, T. (1998) Cyclodextrin drug
UEKAMA, K. (1990) Utility of 2-hydroxypropyl-beta-cyclo-
carrier systems. Chemical Reviews, 98: 2045–2076.
dextrin in an intramuscular injectable preparation of
VARGAS, D., GUTIE´RREZ, L., JUA´REZ, I., GONZA´LEZ, F. &
SUMANO, H. (2008) Pharmacokinetics of an injectable
Downloaded by [UNAM Ciudad Universitaria] at 11:09 14 February 2013
Use of Life Cycle Assessment in Evaluating Solvent Recovery Alternatives in Pharmaceutical Manufacture William A. Carole, C. Stewart Slater, Mariano J. Savelski*, Timothy Moroz, Anthony Furiato, Kyle Lynch Rowan University, Dept. of Chemical Engineering 201 Mullica Hill Rd., Glassboro, NJ 08028, USA Keywords: pharmaceutical manufacture, solvent recovery, pervaporation, life cycle asse
ANNUAL RETURN LODGEMENT FOR CLOSE CORPORATIONS Frequently Asked Questions Version 1.3 Version: Date Created/Updated: Why does a close corporation have to lodge Annual Returns? That the close corporation’s information is up to date with CIPRO; and That the close corporation is still doing business. It is a statutory duty that is contained within the Close